国家公務員共済組合連合会 虎の門病院は、東京都港区虎ノ門二丁目にある病院である。設置者は国家公務員共済組合連合会。2次救急指定告示医療機関、臨床研修指定病院であると共に、東京都の肝疾患診療連携拠点病院に指定されている。

During the past decade, Toranomon Hospital conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 20 clinical trials were completed, i.e. on average, 69% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 15 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Toranomon Hospital" #1 sponsor was "Celgene" with 7 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Haruhiko Fukuda" with 4 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored and "Gilead Sciences" with 3 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Toranomon Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 6 trials as a collaborator, "AstraZeneca" with 4 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "Korean Cancer Study Group" with 2 trials as a collaborator and "BeiGene" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Toranomon Hospital" are "Nonalcoholic Steatohepatitis" (4 trials), "Breast Cancer" (3 trials), "Lymphoma, Non-Hodgkin" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials) and "Chronic Hepatitis C" (2 trials). Many other conditions were trialed in "Toranomon Hospital" in a lesser frequency.

Most popular intervention types in "Toranomon Hospital" are "Drug" (40 trials), "Other" (4 trials), "Procedure" (4 trials), "Device" (2 trials) and "Genetic" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Rituximab" (4 trials), "DS-8201a" (3 trials), "Nintedanib" (3 trials) and "BMS-986036" (2 trials). Other intervention names were less common.

The vast majority of trials in "Toranomon Hospital" are 43 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Toranomon Hospital". undefined are not yet recruiting, 3 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Toranomon Hospital, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Toranomon Hospital, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".